Disease · MONDO_0044704
oropharynx squamous cell carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. oropharynx squamous cell carcinoma. Diseases, record MONDO_0044704. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044704
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
epidermoid carcinoma of oropharynx, epidermoid carcinoma of the oropharynx, oropharyngeal epidermoid carcinoma, oropharyngeal squamous cell carcinoma, oropharyngeal throat squamous cell cancer, squamous cell carcinoma of oropharynx
- Open Targets
Drugs52
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 47 | 47 | 47 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 3 | ClinicalTrials.gov | 17 | 17 | 17 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AVELUMAB | CHEMBL3833373 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PANITUMUMAB | CHEMBL1201827 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRETINOIN | CHEMBL38 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VINFLUNINE | CHEMBL2110725 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 52
See all 52 drugsTargets122
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 7 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 6 | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 4 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| TUBA1A | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
| TUBB | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/203068 | Drugs and targets |
1 to 10 of 122
See all 122 targetsTrials87
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00265941 | Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer | Phase 3 | 940 | 2017-12-21 | Head and Neck Cancer | CETUXIMAB, CISPLATIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00047008 | Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer | Phase 3 | 743 | 2014-08-15 | Head and Neck Cancer | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02952586 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) | Phase 3 | 697 | 2021-02-24 | Squamous Cell Carcinoma of the Head and Neck | AVELUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | Phase 2 | 519 | 2022-09-28 | Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx | CARBOPLATIN, CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02347332 | Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer | Phase 3 | 459 | 2019-02-04 | Recurrent or Metastatic Head and Neck Carcinoma | METHOTREXATE, VINFLUNINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02254278 | Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer | Phase 2 | 316 | 2020-08-12 | Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02908477 | Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer | Phase 3 | 228 | 2024-04-08 | Oropharynx Cancer | CISPLATIN, DOCETAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT02281955 | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study | Phase 2 | 115 | 2020-12-22 | Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03822897 | De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma | Phase 2 | 103 | 2025-09-30 | Oropharyngeal Cancer | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02573493 | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Phase 2 | 96 | 2021-03-02 | Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck | CETUXIMAB, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 87
See all 87 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| RT + Cisplatin vs RT + Cisplatin + Cetuximab: serious adverse events | 208 of 447 | 237 of 444 | 891 | NCT00265941 | Trial comparisons |
| Standard Fractionation RT + Cisplatin vs Accelerated Fractionation RT + Cisplatin: serious adverse events | 293 of 361 | 279 of 360 | 721 | NCT00047008 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: deaths from any cause | 86 of 348 | 62 of 344 | 692 | NCT02952586 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: serious adverse events | 184 of 348 | 177 of 344 | 692 | NCT02952586 | Trial comparisons |
| Vinflunine Plus Methotrexate vs Methotrexate: deaths from any cause | 185 of 225 | 194 of 227 | 452 | NCT02347332 | Trial comparisons |
| Vinflunine Plus Methotrexate vs Methotrexate: serious adverse events | 106 of 225 | 81 of 227 | 452 | NCT02347332 | Trial comparisons |
| IMRT 6 Weeks + Cisplatin vs IMRT 5 Weeks: deaths from any cause | 6 of 152 | 6 of 147 | 299 | NCT02254278 | Trial comparisons |
| IMRT 6 Weeks + Cisplatin vs IMRT 5 Weeks: serious adverse events | 31 of 152 | 11 of 147 | 299 | NCT02254278 | Trial comparisons |
| De-escalated Adjuvant Radiation Therapy (DART) vs Standard of Care Treatment (SOC): deaths from any cause | 2 of 136 | 9 of 92 | 228 | NCT02908477 | Trial comparisons |
| De-escalated Adjuvant Radiation Therapy (DART) vs Standard of Care Treatment (SOC): serious adverse events | 0 of 136 | 1 of 92 | 228 | NCT02908477 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials69
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044704
GET https://conductscience.org/api/diseases/v1/MONDO_0044704/drugs?page=2